Diseases & Conditions Market Research Reports & Industry Analysis
Insomnia is a common condition in which one has trouble going to sleep or staying asleep. This condition can range from weak to strong, depending on how often it occurs and for how long. Insomnia can be ongoing or acute. Chronic insomnia means having symptoms at least 3 nights a week for more than a month. Acute insomnia lasts for less time. Some people who have insomnia will have trouble falling asleep. Other people may fall asleep easily but, then wake up.
Diseases & Conditions Industry Research & Market Reports
-
Latent TB Testing Market by Test Type (Tuberculin Skin Test/TST, IGRA Test), Application (Household Contacts (HHC) of Tuberculosis (TB) Patients, People Living with HIV), End User (Diagnostic Labs, Hospitals), Region - Global Forecast to 2029
... The latent TB testing market will rise in value from estimated USD 582.5 million in 2024 to USD 773.4 million in 2029, at a CAGR of 5.8% over the forecast period. Increased funding and grants ... Read More
-
Neglected Tropical Diseases Diagnosis
... reach US$10.3 Billion by 2030, growing at a CAGR of 5.4% over the analysis period 2023-2030. Conventional Method, one of the segments analyzed in the report, is expected to record a 4.8% CAGR and reach ... Read More
-
Oncology Based In-Vivo CRO
... reach US$2.5 Billion by 2030, growing at a CAGR of 7.0% over the analysis period 2023-2030. Solid Tumors Indication, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and ... Read More
-
Global Epilepsy Therapeutics Market (2024 Edition): Analysis By Generation (First Generation, Second Generation, Third Generation), By Route of Administration, By Type, By Region, By Country: Market Insights and Forecast (2020-2030)
... released a research report titled “Global Epilepsy Therapeutics Market (2024 Edition)” which provides an analysis of the Global Epilepsy Therapeutics industry in terms of market segmentation By Generation (First Generation, Second Generation, Third Generation), By ... Read More
-
Nanocapsules
... of 6.3% over the analysis period 2023-2030. Oncology Therapy Area, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$2.0 Billion by the end of the analysis ... Read More
-
Pesticide Inert Ingredients
... by 2030, growing at a CAGR of 6.1% over the analysis period 2023-2030. Emulsifiers, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$3.3 Billion by the ... Read More
-
Diabetic Foot Ulcers and Pressure Ulcers
... the year 2023, is expected to reach US$6.0 Billion by 2030, growing at a CAGR of 4.4% over the analysis period 2023-2030. Diabetic Foot Ulcers, one of the segments analyzed in the report, is expected ... Read More
-
Calcium Channel Blockers
... by 2030, growing at a CAGR of 6.1% over the analysis period 2023-2030. Dihydropyridine Drug Class, one of the segments analyzed in the report, is expected to record a 6.5% CAGR and reach US$17.1 Billion ... Read More
-
Microwave Ablation
... at a CAGR of 13.0% over the analysis period 2023-2030. Liver Cancer Application, one of the segments analyzed in the report, is expected to record a 14.9% CAGR and reach US$215.5 Million by the end ... Read More
-
Venturi Masks
... at a CAGR of 11.5% over the analysis period 2023-2030. COPD Application, one of the segments analyzed in the report, is expected to record a 13.5% CAGR and reach US$2.9 Billion by the end of ... Read More
-
Insulin Pens
... at a CAGR of 7.1% over the analysis period 2023-2030. Disposable Insulin Pens, one of the segments analyzed in the report, is expected to record a 7.7% CAGR and reach US$11.6 Billion by the end ... Read More
-
Diabetic Shoes
... at a CAGR of 8.1% over the analysis period 2023-2030. Online Distribution Channel, one of the segments analyzed in the report, is expected to record a 8.4% CAGR and reach US$10.6 Billion by the end ... Read More
-
Desmopressin
... of 5.5% over the analysis period 2023-2030. Injectable Solution, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$866.1 Million by the end of the analysis period. ... Read More
-
Ambulatory Electronic Health Record (EHR)
... is expected to reach US$9.9 Billion by 2030, growing at a CAGR of 6.1% over the analysis period 2023-2030. Cloud Deployment, one of the segments analyzed in the report, is expected to record a 6.4% ... Read More
-
Basal Cell Carcinoma Treatment
... reach US$12.4 Billion by 2030, growing at a CAGR of 8.0% over the analysis period 2023-2030. Surgery Treatment, one of the segments analyzed in the report, is expected to record a 8.6% CAGR and reach ... Read More
-
Biochemical Reagents
... at a CAGR of 8.7% over the analysis period 2023-2030. PCR Reagent Kits, one of the segments analyzed in the report, is expected to record a 11.0% CAGR and reach US$6.3 Billion by the end ... Read More
-
Extracorporeal CO2 Removal Devices
... reach US$151.9 Million by 2030, growing at a CAGR of 5.9% over the analysis period 2023-2030. Extracorporeal CO2 Machines, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and ... Read More
-
LED Video Walls
... by 2030, growing at a CAGR of 6.9% over the analysis period 2023-2030. Indoor Deployment, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$2.0 Billion by ... Read More
-
Nail Care
... at a CAGR of 2.5% over the analysis period 2023-2030. Nail Polishes, one of the segments analyzed in the report, is expected to record a 2.8% CAGR and reach US$8.3 Billion by the end of ... Read More
-
Sarcoma Drugs
... at a CAGR of 7.5% over the analysis period 2023-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$1.9 Billion by the end of ... Read More
-
Type 2 Diabetes - Pipeline Insight, 2024
... pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. ... Read More
-
Cutaneous T-cell lymphoma - Pipeline Insight, 2024
... drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography ... Read More
-
Restorative Dentistry
... at a CAGR of 8.3% over the analysis period 2023-2030. Restorative Materials, one of the segments analyzed in the report, is expected to record a 9.4% CAGR and reach US$19.4 Billion by the end of ... Read More
-
Veterinary Pain Management
... by 2030, growing at a CAGR of 7.7% over the analysis period 2023-2030. Pain Management Drugs, one of the segments analyzed in the report, is expected to record a 8.0% CAGR and reach US$2.1 Billion ... Read More
-
Hematological Malignancies
... at a CAGR of 6.2% over the analysis period 2023-2030. Leukemia Disease, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$33.3 Billion by the end of ... Read More
Research Assistance
